Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CLVSQ: BK PLAN effective. All shares cancelled.
https://otce.finra.org/otce/dailyList?viewType=Deletions
The company warns: "Cautionary Statements Regarding Trading in the Company’s Securities
The Company’s securityholders are cautioned that trading in the Company’s securities during the pendency of the Cases is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Cases. The Company currently does not expect that holders of the Company’s common stock will receive any payment or other distribution on account of those shares in the Cases given the expected sales proceeds (including the highly contingent nature of certain later milestone payments) and the amount of the Debtors’ liabilities to more senior creditors. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities."
May 1, 2023
https://www.otcmarkets.com/filing/html?id=16609281&guid=nRu-kq6BxCkHJth
Going out of BK and commons to be deleted.
CLVS changed to CLVSQ, bankruptcy. Delisted from the Nasdaq to the OTC:
https://otce.finra.org/otce/dailyList?viewType=Additions
$CLVS: Another Chamatch Clusterphuck
He scammed sooooooooooooooooooo many.... nothing new here
YIKES
Buy it at 0.01
They Filed Bankruptcy
Elite Pharmaceuticals (otcqb: ELTP) = CASH FLOW POSITIVE for about 2 years now with low debt. Unbelievably suppressed stock price @ 3.5 cents. Year 2021 revenue is $32 Million. Income from Operations before taxes is $6.3 Million. Net income attributable to common shareholders is $8.9 Million. CEO owns 300 million shares. ELTP historically made couple of Millionaire-making monster runs.
**************** Upward Growth *****************
-FY- ------------------ Revenue ---------------------------------Net Income
2019 ----------------7,568,508----------------------------------- (9,279,321)
2020 ---------------17,994,639----------------------------------- (2,240,351)
2021--------------- 25,380,749------------------------------------ 5,088,421
2022--------------- 32,262,117------------------------------------ 8,898,245
All in the company SEC filings
Outstanding Shares: 1.01 Billion
Float : ~ 750 Million
Latest SEC 10-K Financial Report
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315222018108/form10-k.htm
ELTP primed for the next Millionaire Maker run!!!
2010-2011........................... $0.039- $0.26
2014...................................... $0.060- $0.97
2022-2023........................... $0.035- DollarLand?
Catalysts:
>>> First ever straight generic equivalent of oxycodone. No pharma company has entered the market yet to compete with Oxycodone as a generic.
>>> 2 abuse deterrents generic CNS stimulant
>>> ADF adderall
>>> Very rare to find an otc listed company with CASH FLOW POSITIVE status.
$CLVS Friday trading makes me think this is well oversold..see if this gap starts to fill this week..
https://stockcharts.com/c-sc/sc?s=CLVS&p=D&b=5&g=0&i=0&r=1668346629422
"" a potential bankruptcy"
Companies don't put out "potential" events or news because it's a SEC and lawsuit risk.
This smells like an illegal attempt to drop the share price or scare existing investors into selling.
Just an opinion.
Just saw that. I was looking into CLVS yesterday and this morning. Wondering now if this is playing on the other one you posted on. ATH*. It almost would make sense as far as desperation goes in this sector. Shorts making out like bandits.
GL
From 10Q " a potential bankruptcy filing in the very near term looks
increasingly probable"
Wow a whole .01 increase and how much did this CEO spend to get that and he is still CEO?
Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line Maintenance
9:11 am ET September 12, 2022 (Benzinga) Print
Clovis Oncology Inc (NASDAQ: CLVS) announced results from a subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca versus placebo in advanced ovarian cancer.
The data showed that Rubraca as a first-line maintenance treatment improved progression-free survival (PFS) versus placebo across disease risk subgroups, including surgical outcome, response to first-line chemotherapy, and additional analyses in other subgroups.
Patients who received Rubraca as maintenance therapy showed benefit regardless of surgical outcome, whether there was complete resection (R0) during cytoreductive surgery or not.
Among HRD-positive patients:
Patients who demonstrated a partial response to first-line chemotherapy; Rubraca (n=33), median PFS of 14.8 months; placebo (n=9), median PFS of 9.1 months.
Patients who demonstrated a complete response to first-line chemotherapy; Rubraca (n=38), median PFS of 25.8 months; placebo (n=4), median PFS not yet reached.
Among the ITT population:
Patients who demonstrated a partial response to first-line chemotherapy; Rubraca (n=76), median PFS of 12.2 months; placebo (n=22), median PFS of 6.4 months.
Patients who demonstrated a complete response to first-line chemotherapy; Rubraca (n=73), median PFS of 15.6 months; placebo (n=11), median PFS of 6.4 months.
Safety was similar between the subgroups analyzed.
Price Action: CLVS shares are up 13% at $1.30 during the premarket session on the last check Monday.
Clovis Oncology shares are trading higher after the company presented data from its Phase 3 ATHENA trial which showed Rubraca as a first-line maintenance treatment improved progression-free survival in advanced ovarian cancer.
You nailed it lmfao
The mms have been propping the bid price for weeks while slowly declining or this would have hit bottom by now . I don’t have a clue for what reason why. Just been watching it day to day .
I just put this on radar but so far the bottom doesn't even look close yet. In fact, according to my charts the downward momentum is just starting to pick up. Looks very close to crack time.
CLVS daily
Their science may still win and the potential for partnership looks appetizing but if their science is that promising, what's taking so long? Crazy burn rate too but also a lot happening.
I put this on my watchlist but for this one it'll need to prove a bottom for me 1st.
Cheers
All IMO of course.
MM must have 1 dollar calls for this Friday or this would of dropped by now. they keep putting up fake walls to manipulate the share cost. The out put has been higher than the input all day and only dropped .06 they just keep adding shares to the bid as they get close to dropping. This will drop so hard tomarrow .
Tomarrow will be worse. 10 drop nothing to keep this up but hope.
Yep just has I figured no money to stay afloat . Will go way down below a dollar. Good luck .
Zacks has posted a message to brace for bad news on earning this past quarter. Question is how bad?
Don't think were at the bottom yet, with so much shorting. Still thinking around or below a dollar, That's just my opinion on what i see! Does any one else want to chime in or have some information?
New information on short interest for CLVS ,0ver 30 percent and climbing. do your own DD!
https://shortsqueeze.com/shortinterest/stock/term2.phps=CLVS#:~:text=%20%20%20Short%20Squeeze%20Ranking%E2%84%A2%20%20,%20%202.6%20%203%20more%20rows%20
This is going a lot more down than 2.02
What a complete piece of crap the CEO is. Zero communication.
Democrat policies are the cause of inflation. They were going up continuously even before the war.
Believe it or not a recession is coming . Look at the latest inflation 9.1 numbers and the upcoming rate hike in July. They are doing this on purpose. Even the bond market is moving up.
Will go below a dollar watching the trend.
Won’t get there
No clue what a CTU trader is
I am a CTU trader, lol it's all good for me, gltu.
2.15 after hours. Utterly pitiful
Followers
|
77
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
813
|
Created
|
09/25/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |